Patient's Life Ability With Malignant Astrocytoma Grade IV

Lilik Widodo, Andi Asadul Islam, Djoko Widodo, Joni Wahyuhadi

Abstract


Grade IV astrocytoma is a primary brain tumor with a high mortality rate. The survival time for astrocytoma grade IV is about 6-12 months. Conventional therapies that exist to date in the form of surgery, radiation and chemotherapy. The main problem with malignant astrocytoma is that tumor cells grow infiltratively into the surrounding brain tissue and are always recurrent despite conventional therapy. This condition results from a complex gliomagenesis process involving the role of neural cancer stem cells (NCSC). The lack of an efficient immune response and the micro-invasive nature of malignant astrocytoma cells has been explained by many immune surveillance mechanisms in brain malignancies. The survival ability of these tumors results in a complex interaction between the tumor and the body's immune system. The aim of this study was to evaluate the survival time of malignant astrocytoma grade IV  patients treated with surgery, radiotherapy with or without chemotherapy. A retrospective study of the survival time of patients with malignant astrocytoma grade IV treated by us during the period 2005 - 2015 was 12 patients. All patients postoperative craniotomy resection of tumors undergoing radiation with 42 Gay. Among these 6 patients received chemotherapy as well. Sexually male proportion more than female with ratio 1.6 : 1. Most were over 50 years old (83%), 2 patients under the age of 50 years. Four patients (33%) survived for one year, survived for two years found 5 patients (41%), survived more than 3 years 3 patients (25%) and none survived more than 5 years .. This syudy suggests that chemotherapy have no effect on the survival time of the patient.


Keywords


astrocytoma grade IV; survival; conventional therapy.

Full Text:

PDF

References


. Arvold ND, Reardon DA, (2014). “Treatment options and outcomes for glioblastoma in the elderly patient”, Clinical Investigations in Aging. (9) : 357-367.

. Accettura C, Cocciolo A, et all , (2014). “High grade glioma management : focus on elderly patients” http://www.reviewsinoncology.com/materiale_cic/837_2_3/7142_high/article.htm, 2(3); 67-72

. Van den Bent, MJ, (2006). “Adjuvant treatment of high grade glioma”. Annals of oncology (17): x186-x190.

. Bruce JN, (2016). “ Brain Cancer Treatment Protocols”. Medscape , Dec 13.

. Hart MG, Garside, et all, (2016). “Temozolomide for high grade glioma (Review)”. Cochrane Library , Issue 4. Art CD007415.

. Missirliu A. (2015). “Retropsective Study of High Grade Astrocytoma “Stupp Treatment” Outcome at the Orebro University Hospital”. Orebro University,Faculty of Medicine and Health.

. Narayanan, et all. (2012). “High Grade Glioma: Pathogenesis, Management and Prognosis”. Neurosurgery (10): 1-17.

. 8.Oshiro S, Tsugu H, et all. (2009). Efficacy of Temozolomide Treatment in Patients with High grade Glioma”. Anticancer Research (29)3 : 911-917

. Perez-Larraya JG, Delattre JY.(2014). “Management of Elderly Patients with Glioma”. The Oncologist. (19) : 1258-1267.

. Snyder J, Walbert T. (2017). “Managing Glioblastoma in the Elderly Patient: New Opportunities”. Oncology Joournal,Brain Tumors.Vol 31, issue : 6.

. Yiallouros M. (2016). “High Grade Gliomas(HGG)- Brief Information”. Kinderkresinfo.de.


Refbacks

  • There are currently no refbacks.

Comments on this article

View all comments


 

 
  
 

 

  


About IJSBAR | Privacy PolicyTerms & Conditions | Contact Us | DisclaimerFAQs 

IJSBAR is published by (GSSRR).